U.S. FDA Approves Jaypirca(TM) (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor.
In: PR Newswire, 2023-01-27
Zeitungsartikel
Zugriff:
Titel: |
U.S. FDA Approves Jaypirca(TM) (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma After at Least Two Lines of Systemic Therapy, Including a BTK Inhibitor.
|
---|---|
Zeitschrift: | PR Newswire, 2023-01-27 |
Veröffentlichung: | 2023 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|